Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Reduction of risk of NSAID-associated gastric ulcers in patients at risk who require continuous NSAID treatment.
* Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Maintenance of Healing of Erosive Esophagitis:** 40 mg orally once daily. Some patients may be managed on 20 mg orally once daily.
* **Reduction of NSAID-Associated Gastric Ulcers:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be increased up to 240 mg intravenously or 120 mg orally per day, divided into two doses.
## Pediatric Dosing
Dosing in pediatric patients is highly variable and depends on age, weight, and indication. Specific recommendations vary by guideline and formulary.
* **Children 12 years and older:**
* Healing of Erosive Esophagitis: 40 mg orally once daily for up to 8 weeks.
* GERD: 20 mg to 40 mg orally once daily.
* **Children younger than 12 years:** Oral and IV formulations have different dosing considerations. Consult specific pediatric guidelines or prescribing information.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment, though caution is advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other benzimidazoles.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use of PPIs may be associated with increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **CYP2C19 and CYP3A4 Substrates:** Pantoprazole can decrease gastric pH, which may affect the absorption of other drugs (e.g., ketoconazole, itraconazole, posaconazole, dasatinib, erlotinib, and certain antiretrovirals).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **Voriconazole:** Coadministration may increase voriconazole concentrations.
* **Clopidogrel:** Consider the potential for reduced antiplatelet effect due to CYP2C19 inhibition, though clinical significance is debated.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea.
* Consider periodic monitoring of serum magnesium levels, especially in patients on long-term therapy or taking concomitant medications like diuretics.
* Monitor for signs and symptoms of bone fractures.
## Clinical Pearls
* Intravenous pantoprazole is generally reserved for situations where oral administration is not feasible.
* Take oral pantoprazole at least 30 minutes before a meal.
* Do not crush or chew delayed-release formulations.
***
**Disclaimer:** This information is intended for clinical use and does not replace comprehensive prescribing information. Always verify current prescribing information and local protocols before administering this medication.
